Pharmaceutical PV DIV - FSB
Ended Awarded
- Contract number
- SPE2DU26FEMLZ
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $177,446
Award facts
- Contract value 100% obligated
- $177,446.25 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a $177,446.25 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois. The delivery order, issued on October 23, 2025, with an ultimate completion date of October 24, 2025, was awarded without a set-aside designation, demonstrating the contractor's competitive capability in unrestricted federal procurement. DMS Pharmaceutical Group will deliver pharmaceutical products and medical consumables to support Department of Defense healthcare operations, with performance at the company's Park Ridge, Illinois location. The company has been registered in the System for Award Management since July 2001 and maintains no identified subcontractor relationships on this award.
This delivery order is issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion acquisition strategy designed to establish regional prime vendor contractors supplying comprehensive pharmaceutical products to military healthcare facilities worldwide. The underlying IDC, designated SPE2DR and awarded November 13, 2025, carries a $500 million ceiling value and extends through December 31, 2036, with a 30-month base period and three 30-month option periods. DMS Pharmaceutical Group's product portfolio includes branded and generic prescription medications, over-the-counter drugs, biologics, vaccines, and specialty pharmaceuticals, positioning the company as a critical supplier within the federal military medical supply chain.
Quick answers
Who was awarded contract SPE2DU26FEMLZ?
SPE2DU26FEMLZ was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on October 23, 2025.
How much is contract SPE2DU26FEMLZ worth?
The government has obligated $177,446 on SPE2DU26FEMLZ.
Is contract SPE2DU26FEMLZ an order under another contract?
Yes. SPE2DU26FEMLZ is a delivery order under SPE2DU25D9517, an indefinite delivery contract.
Was contract SPE2DU26FEMLZ competed?
The extent of competition for SPE2DU26FEMLZ was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award